Literature DB >> 32328824

Comprehensive Analysis of Adverse Events Associated with Gastric Peroral Endoscopic Myotomy: An International Multicenter Study.

Y Ichkhanian1, K Vosoughi1, M Aghaie Meybodi1, J Jacques2, A Sethi3, A A Patel3, A A Aadam4, J R Triggs4, A Bapaye5, S Dorwat5, P Benias6, D M Chaves7, M Barret8,9, R J Law10, N Browers10, M Pioche11, P V Draganov12, A Kotzev13, F Estremera13, E Albeniz14, M B Ujiki15, Z M Callahan15, M I Itani1, O G Brewer1, M A Khashab16,17.   

Abstract

BACKGROUND: Gastric peroral endoscopic myotomy (G-POEM) has emerged as an effective management approach for patients with refractory gastroparesis. This study aims to comprehensively study the safety of G-POEM and describe the predictive factors of adverse events (AEs) occurrence.
METHODS: This study is a retrospective study involving 13 tertiary care centers (7 USA, 1 South America, 4 Europe, and 1 Asia). Patients who underwent G-POEM for refractory gastroparesis were included. Cases were identified by the occurrence of AEs. For each case, two controls were randomly selected and matched for age (± 10 years), gender, and etiology of gastroparesis.
RESULTS: A total of 216 patients underwent G-POEM for gastroparesis. Overall, 31 (14%) AEs were encountered [mild 24 (77%), moderate 5 (16%), and severe 2 (6%)] during the duration of the study. The most common AE was abdominal pain (n = 16), followed by mucosotomy (n = 5) and capnoperitoneum (n = 4), and AEs were most commonly identified within the first 48-h post-procedure 18 (58%). The risk of adverse event occurrence was significantly higher for endoscopists with experience of < 20 G-POEM procedures (OR 3.03 [1.03-8.94], p < 0.05).
CONCLUSION: G-POEM seems to be a safe intervention for refractory gastroparesis. AEs are most commonly mild and managed conservatively. Longitudinal mucosal incision, use of hook knife, use of clips for mucosal closure and endoscopist's experience with > 20 G-POEM procedures is significantly associated with decreased incidence of AEs.

Entities:  

Keywords:  Adverse events; G-POEM; Gastric peroral endoscopic myotomy; Gastroparesis

Mesh:

Year:  2020        PMID: 32328824     DOI: 10.1007/s00464-020-07570-z

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  1 in total

1.  Temporary dumping syndrome after gastric peroral endoscopic myotomy: should we control the glycemia?

Authors:  Typhaine Louazon; Jérome Rivory; Sabine Roman; François Mion; Thierry Ponchon; Mathieu Pioche
Journal:  Endoscopy       Date:  2016-01-22       Impact factor: 10.093

  1 in total
  5 in total

1.  Endoscopic clips versus overstitch suturing system device for mucosotomy closure after peroral endoscopic pyloromyotomy (G-POEM): a prospective single-center study.

Authors:  R Hustak; Z Vackova; J Krajciova; J Spicak; E Kieslichova; J Mares; Jan Martinek
Journal:  Surg Endosc       Date:  2022-07-18       Impact factor: 3.453

2.  Navigational tunnel technique for gastric peroral endoscopic pyloromyotomy: getting straight to the point (pylorus).

Authors:  Jennifer M Kolb; Piotr Sowa; Jason Samarasena; Kenneth J Chang
Journal:  VideoGIE       Date:  2021-10-27

3.  Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial.

Authors:  Jan Martinek; Rastislav Hustak; Jan Mares; Zuzana Vackova; Julius Spicak; Eva Kieslichova; Marie Buncova; Daniel Pohl; Sunil Amin; Jan Tack
Journal:  Gut       Date:  2022-04-25       Impact factor: 31.793

4.  Evaluation of the safety profile of endoscopic pyloromyotomy by G-POEM: a French multicenter study.

Authors:  Florian Baret; Jeremie Jacques; Mathieu Pioche; Jeremie Albouys; Véronique Vitton; Geoffroy Vanbiervliet; Antoine Debourdeau; Marc Barthet; Jean-Michel Gonzalez
Journal:  Therap Adv Gastroenterol       Date:  2022-10-03       Impact factor: 4.802

5.  Effective factors of peroral endoscopic myotomy for treatment of achalasia.

Authors:  Qianyi Liu; Weishan Ruan; Zhishang Liu; Jiefeng Li; Jiayan Li
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2022-03-27       Impact factor: 1.627

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.